Table 1.

Characteristics of patients with IBD treated with infliximab.

	Patients (n = 57)
Age at diagnosis, median (IQR), years	29 (19–36)
Gender, n (%)
Female	32 (56.1)
Male	25 (43.9)
Crohn’s disease, n (%)	40 (70.2)
Ulcerative colitis, n (%)	17 (29.8)
Smoking status, n (%)
Never smoker	33 (57.9)
Former smoker	16 (28.1)
Current smoker	8 (14.0)
Concomitant IBD-related medication, n (%)
None	21 (36.8)
Azathioprine	19 (33.3)
Steroids	9 (15.8)
Methotrexate	3 (5.3)
Oral 5-aminosalicylates	5 (8.8)
Time under biological therapy, median (min–max), months	6 (1–20)
IFX mg/kg, median (min–max)	6 (5–10)
Number of IFX received, median (min–max)	3 (0–12)
Dose intervals, median (min–max)	7 (5–8)
Dose optimization, n (%)
No	47 (82.5)
Yes	10 (17.5)
Albumin g/l, median (min–max)	41.9 (29.3–66.4)

IBD, inflammatory bowel disease; IFX, infliximab, IQR, interquartile range; n, number of patients.